Cala Health Secures $50M Growth Capital From Trinity Capital

Why It Matters

The infusion strengthens Cala's balance sheet, enabling rapid market expansion and product innovation in a high‑need neuromodulation niche, while signaling investor confidence in wearable bio‑electronics as a therapeutic class.

Key Takeaways

• Cala secured $50M growth capital from Trinity Capital.
• TAPS therapy targets tremors in Parkinson’s and essential tremor patients.
• FDA cleared Cala kIQ Plus expands home‑use treatment options.
• Funding brings total capital to over $182M since 2019.

Pulse Analysis

Wearable neuromodulation is emerging as a disruptive force in chronic‑disease management, and Cala Health sits at the forefront with its TAPS platform. By measuring a patient’s tremor signature and delivering patterned electrical pulses, the device offers a drug‑free alternative that can be administered at home. This approach aligns with broader trends toward personalized, non‑invasive therapies and addresses a sizable market—estimated at over $5 billion globally for tremor‑related treatments.

The $50 million injection from Trinity Capital not only bolsters Cala’s cash runway but also reshapes its capital structure for scalable growth. Trinity’s expertise in alternative assets provides strategic guidance on go‑to‑market execution, supply‑chain optimization, and potential partnerships with neurologists and health systems. In a competitive landscape that includes both pharmaceutical giants and emerging med‑tech startups, this capital positions Cala to accelerate sales, expand reimbursement pathways, and invest in next‑generation device iterations.

Regulatory momentum further validates the company’s trajectory. Recent FDA 510(k) clearance of the Cala kIQ Plus expands the product line, offering clinicians a broader toolkit for tremor management. As clinicians increasingly prescribe home‑based neuromodulation, patient adoption is expected to rise, driving recurring revenue streams. For investors, Cala’s growing portfolio and robust funding history suggest a compelling long‑term play in the bioelectronic medicine sector, where clinical efficacy and scalable business models are converging.

Deal Summary

Cala Health, a California-based bioelectronic medicine company, announced it has secured $50 million in growth capital from alternative asset manager Trinity Capital. The funding will support commercial expansion and product innovation for its wearable neuromodulation therapy targeting tremor disorders. The round was completed as of the announcement on April 20, 2026.